XGEVA was accepted and granted Orphan Medication Designation by the FDA.

Amgen’s XGEVA receives FDA approval for treatment of hypercalcemia of malignancy Amgen today announced that the U ed help read more .S. XGEVA was accepted and granted Orphan Medication Designation by the FDA, which can be reserved for medications that are intended for the treatment of rare diseases affecting less than 200,000 people in the U.S. HCM is normally a significant complication in individuals with advanced cancer, including those with hematologic malignancies, and indicates poor prognosis. The condition results from cancer-driven boosts in bone resorption, and if untreated, can lead to renal failure, progressive mental impairment, coma and death.

Other Posts From "pharmacy":

Related Posts